159
Participants
Start Date
October 27, 2020
Primary Completion Date
October 13, 2022
Study Completion Date
March 28, 2023
Benralizumab
2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
Placebo and Benralizumab
2 induction doses of benralizumab (dose A and B) compared to placebo, and a comparison of maintenance dosing regimens (B vs A) in the 28-week extension period.
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, Sofia
Research Site, Pleven
Research Site, Haskovo
Research Site, Seoul
Research Site, Rousse
Research Site, Barcelona
Research Site, Berlin
Research Site, Córdoba
Research Site, Madrid
Research Site, Columbus
Research Site, Miami
Research Site, Tampa
Research Site, Cincinnati
Research Site, Cincinnati
Research Site, Manises
Research Site, Ypsilanti
Research Site, Norman
Research Site, Austin
Research Site, Scottsdale
Research Site, Los Angeles
Research Site, Newport Beach
Research Site, Mission Viejo
Research Site, Dresden
Research Site, Leipzig
Research Site, Hiroshima
Research Site, Kamimashikigun,
Research Site, Kawasaki-shi
Research Site, Kobe
Research Site, Sakaishi
Research Site, Gdansk
Research Site, Krakow
Research Site, Poznan
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Seoul
Research Site, Seoul
Research Site, Alicante
Lead Sponsor
Iqvia Pty Ltd
INDUSTRY
AstraZeneca
INDUSTRY